Kite Pharma Announces Exclusive License with the National Institutes of Health for Multiple Neoantigen Directed T-Cell Receptor (TCR) Product Candidates to Treat Solid Tumors Expressing Mutated KRAS
Kite expects the first of the licensed KRAS product candidates to enter
clinical study in 2016 as part of the Company's Cooperative Research and
Development Agreement (CRADA) with the
Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI.
KRAS is one of the most commonly mutated genes in all of human cancer and is involved in a broad range of solid tumors, such as pancreatic, colorectal, and lung cancer, for which there are significant unmet medical needs.
"Neoantigens are uniquely present in tumors but absent in healthy tissue which makes them attractive targets for using our TCR technology," stated
Arie Belldegrun, M.D., FACS, Kite's Chairman, President and Chief Executive Officer. "Kite has taken an important step toward building the first therapeutic franchise of its kind for cancers driven by KRAS mutations and has further expanded its efforts in building a TCR portfolio across key classes of antigens, including cancer testis and viral antigens."
Pursuant to the terms of the license agreement,
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The press release may, in some cases, use terms such as
"predicts," "believes," "potential," "proposed," "continue,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding intentions, beliefs, projections, outlook, analyses
or current expectations concerning, among other things: the ability to
advance and the success of TCR-based product candidates directed against
KRAS antigens and the ability, timing and willingness of the NCI to
continue research and development activities pursuant to the CRADA.
Various factors may cause differences between Kite's expectations and
actual results as discussed in greater detail in Kite's filings with the